Copenhagen-based Lundbeck revealed Wednesday that its migraine drug Vyepti (eptinezumab) failed to demonstrate statistical superiority over placebo at reducing the number of monthly migraine days.
https://www.pharmalive.com/wp-content/uploads/2020/12/Axsome’s-Migraine-Drug-Provides-Relief-in-Phase-III-Trial-BioSpace-12-31-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-08-19 10:25:222022-08-19 11:31:45Lundbeck’s migraine drug hits roadblock in Phase III
